Literature DB >> 14752061

Fast onset medications through thermally generated aerosols.

Joshua D Rabinowitz1, Martin Wensley, Peter Lloyd, Daniel Myers, William Shen, Amy Lu, Craig Hodges, Ron Hale, Daniel Mufson, Alejandro Zaffaroni.   

Abstract

Smoking involves heating a drug to form a mixture of drug vapor and gaseous degradation products. These gases subsequently cool and condense into aerosol particles that are inhaled. Here, we demonstrate rapid and reliable systemic delivery of pure pharmaceutical compounds without degradation products through a related process that also involves inhalation of thermally generated aerosol. Drug is coated as a thin film on a metallic substrate and vaporized by heating the metal. The thin nature of the drug coating minimizes the length of time during which the drug is exposed to elevated temperatures, thereby preventing its thermal decomposition. The vaporized, gas-phase drug rapidly condenses and coagulates into micrometer-sized aerosol particles. For the commonly prescribed antimigraine drug rizatriptan, inhalation of these particles results in nearly instantaneous systemic drug action.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14752061     DOI: 10.1124/jpet.103.062893

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  The effect of film thickness on thermal aerosol generation.

Authors:  Dan J Myers; Ryan D Timmons; Amy T Lu; Ron L Hale; Dennis W Solas; Pravin Soni; Josh D Rabinowitz
Journal:  Pharm Res       Date:  2006-12-19       Impact factor: 4.200

2.  CFD simulations of enhanced condensational growth (ECG) applied to respiratory drug delivery with comparisons to in vitro data.

Authors:  P Worth Longest; Michael Hindle
Journal:  J Aerosol Sci       Date:  2010-08-01       Impact factor: 3.433

Review 3.  Alternative delivery systems for agents to treat acute agitation: progress to date.

Authors:  Kimberly Nordstrom; Michael H Allen
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

4.  Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease--two randomized controlled trials.

Authors:  Nicholas Gross; Leon S Greos; Eli O Meltzer; Selwyn Spangenthal; Robert S Fishman; Daniel A Spyker; James V Cassella
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2014-12       Impact factor: 2.849

5.  Inhaled vs. oral alprazolam: subjective, behavioral and cognitive effects, and modestly increased abuse potential.

Authors:  Chad J Reissig; Joseph A Harrison; Lawrence P Carter; Roland R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  2014-09-09       Impact factor: 4.530

6.  Multiple dose pharmacokinetics of inhaled loxapine in subjects on chronic, stable antipsychotic regimens.

Authors:  Daniel A Spyker; Robert A Riesenberg; James V Cassella
Journal:  J Clin Pharmacol       Date:  2015-05-06       Impact factor: 3.126

Review 7.  Nanomedicine in pulmonary delivery.

Authors:  Heidi M Mansour; Yun-Seok Rhee; Xiao Wu
Journal:  Int J Nanomedicine       Date:  2009-12-29

8.  The effect of the medicine administration route on health-related quality of life: Results from a time trade-off survey in patients with bipolar disorder or schizophrenia in 2 Nordic countries.

Authors:  Tine Rikke Jørgensen; Charlotte Emborg; Karianne Dahlen; Mette Bøgelund; Andreas Carlborg
Journal:  BMC Psychiatry       Date:  2016-07-16       Impact factor: 3.630

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.